In its first-quarter 2025 investor letter, White Falcon Capital Management highlighted stocks such as Grifols, S.A. (NASDAQ:GRFS). Grifols, S.A. (NASDAQ:GRFS) is a plasma therapeutic company.

IBL International has entered a strategic collaboration with healthcare company Grifols to develop biomarker panels for speciality diagnostics. Through this partnership, IBL will develop the ...

In its first-quarter 2025 investor letter, White Falcon Capital Management highlighted stocks such as Grifols, S.A. (NASDAQ:GRFS). Grifols, S.A. (NASDAQ:GRFS) is a plasma therapeutic company. The ...

IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and ...

Private equity firm Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's share price. The Canadian investment group said it ...

About 300 donations have been made at Grifols Hamilton since it opened on March 10 at 2255 Barton St. E. after receiving licensing through Health Canada. Joanna Frketich is the health reporter for ...

"More importantly, their donation directly goes to save patients' lives." Grifols/Biomat USA, which did not respond to messages seeking comment, opened its Erie center in 2014, while Octapharma ...

At their investor event in February 2025, Grifols clearly stated that it would like to integrate Biotest into their larger operations. The simplest means for Grifols to accomplish this ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Parkinson’s disease has always been a complex puzzle, for patients and researchers alike, with contributing factors ranging from overt motor symptoms to hidden molecular interactions. The Michael J.